Method for infusing insulin to a subject to improve impaired hepatic glucose processing

• US 20050137572A1
• Filed: 12/17/2003
• Published: 06/23/2005
• Est. Priority Date: 12/17/2003
• Status: Active Grant

• Current Assignee: Thomas T. Aoki
• Original Assignee: Thomas T. Aoki
• Inventors: Aoki, Thomas T.
• Granted Patent: US 7,682,351 B2
• Time in Patent Office: Days
• US Class Current: 604/504
• CPC Class Codes: A61K 38/28 Insulins

Abstract

The present invention is a method for delivering insulin to a subject to improve impaired hepatic glucose processing. The method delivers a series of pulses of insulin to the subject over a period of time accompanied by ingestion of glucose in the form of a carbohydrate containing meal. The amount of insulin in each pulse, the interval between pulses and the amount of time to deliver each pulse to the subject are selected so that the hepatic processing of glucose is restored in the subject. In subjects whose hepatic glucose processing has been restored there is a subsequent fall in circulating blood glucose levels of 50 mg/dl or more directly as a result of improved hepatic glucose processing.

Claims

1. A method for infusing insulin to a subject to improve impaired hepatic glucose processing comprising the steps of:

a. determining a steady baseline circulating glucose level of the subject and obtaining a subsequent circulating glucose level at least every 30 minutes, the steady baseline circulating glucose level being two consecutive circulating glucose levels about 200 milligrams per deciliter measured five minutes apart,

b. having the subject ingest a carbohydrate containing meal,

c. administering a quantity of insulin through an intravenous site until the subsequent circulating glucose level shows an improvement over the steady baseline circulating glucose level, the improvement over the steady baseline circulating glucose level being a 50 milligram per deciliter or more fall from the steady baseline circulating glucose level within two hours of administering the quantity of insulin, the subsequent circulating glucose level improvement over the steady baseline circulating glucose level being a measurement of sufficient quantity of insulin to achieve an improvement in hepatic glucose processing,

d. allowing the subject to rest at least one hour,

e. repeating steps a-d at least two times.

2. The method of claim 1, wherein the carbohydrate containing meal contains 40 to 100 grams of glucose.

3. The method of claim 1 wherein the intravenous site further comprises a needle or catheter located in the subject'"'"'s body, hand or forearm

4. The method of claim 1, wherein the quantity of insulin contains 10 to 200 milliunits of insulin per kilogram of body weight.

5. The method of claim 1, wherein the quantity of insulin is delivered every 3 to 30 minutes.

6. The method of claim 1, wherein the quantity of insulin is delivered as a series of pulses of insulin over a period of 6 to 180 minutes.

7. The method of claim 1, wherein the quantity of insulin is administered by an intravenous infusion device.

8. The method of claim 1, wherein the quantity of insulin is administered by a syringe.

9. The method of claim 1, wherein the intravenous site is converted to a heparin or saline lock during the rest period.

10. The method of claim 1, wherein said steps a-e are repeated at least one a week.

11. The method of claim 1, wherein said steps a-e are repeated three or more time a week.

12. The method of claim 1, wherein the improvement in hepatic glucose processing is used to lower levels of hemoglobin Alc.

13. The method of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related nephropathy.

14. The method of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related retinopathy.

15. The method of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of diabetes related neuropathy.

16. The method of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of cardiovascular disease.

17. The method of claim 1, wherein the improvement in hepatic glucose processing is used to delay the onset or slow the progression of heart disease.

18. The method of claim 1, wherein the improvement in hepatic glucose processing is used for treating wounds, promoting healing and avoiding amputations in diabetic subjects.

19. The method of claim 1, wherein the improvement in hepatic glucose processing is used to improve mental function in subjects with senile dementia.